HERZLIYA, Isra'ila, da CALGARY, Alberta - Innocan Pharma Corporation, kamfanin fasahar harhada magunguna da ke mai da hankali kan haɓaka sabbin fasahohin isar da magunguna yana farin cikin sanar da sakamakon haɗin gwiwar kuɗin da aka tantance na shekarar da ta ƙare Disamba 31, 2023.

Cikakkiyar Shekarar 2023 Babban Haɗin Kuɗi

• Kudaden shiga ya karu da kashi 534% duk shekara zuwa dalar Amurka miliyan 13.7, idan aka kwatanta da dalar Amurka miliyan 2.6 a shekarar 2022. Wannan gagarumin karuwar kudaden shiga ya samo asali ne saboda kwazon tallace-tallace na reshen Innocan, BI Sky Global Ltd.
• Babban Riba ya karu da kashi 568% duk shekara zuwa dala miliyan 12.0 na shekarar da ta kare a Disamba 31, 2023, idan aka kwatanta da dalar Amurka miliyan 2.1 na 2022.
• Asarar aiki ta ragu da kashi 61% zuwa dalar Amurka miliyan 3.8 a shekarar 2023, idan aka kwatanta da dalar Amurka 6.3 a shekarar 2022.
• Kamfanin ya kammala haɓaka dala miliyan 1.5 a cikin Maris 2024.

Bayanin Gudanarwa

Iris Bincovich, Shugaba na Innocan yayi sharhi: "Mun gamsu sosai da ayyukanmu a cikin 2023, tare da rufe shekara tare da kwata na huɗu mai ƙarfi. Wannan ya faru ne saboda tsananin kisa da ƙungiyarmu ta yi a cikin kwata da kuma cikin shekara. Mun isar da ingantacciyar ƙima, ƙididdigewa ga abokin ciniki kuma mun gudanar da tunani cikin tunani duk bangarorin aikinmu. Abubuwan da muka cim ma a cikin wannan shekarar da kuma ci gaban da muka samu kan aiwatar da dabarunmu ya ba mu damar wuce maƙasudin kuɗinmu na 2023. ”

"Muna bin amincewar FDA na dandalin liposome da aka ɗora LPT na CBD wanda ke sauƙaƙe daidaitaccen allurai da sarrafa sakin CBD a cikin rafin jini don amfani da marasa lafiya da ke fama da ciwo na yau da kullun." ta ci gaba Ms. Bincovich. "Muna ci gaba da jajircewa kan hangen nesanmu. Tabbas lokaci ne mai ban sha'awa ga Innocan Pharma da masu hannun jarinmu. "

Roni Kamhi, Shugaba BI Sky Global da COO na Innocan Pharma sun yi sharhi: “Miliyoyin abokan ciniki sun amince da samfuran lafiyar masu amfani da mu. Mu a BI Sky Global mun yi farin ciki da sakamakon 2023. Mun yi amfani da zurfin fahimtarmu game da sararin kayan shafawa tare da sanin yadda muke amfani da bayanai da nazari don ganowa da mafi kyawun sabis na abokan cinikinmu. Muna kuma fatan kara karfafa BI Sky Global a matsayin jagora a cikin kyawun sararin samaniya da samfuran kulawa na sirri. "

Don ƙarin cikakkun bayanai game da innocan's innocan's audited con consolidated financial statements and related management's tattaunawa da bincike na shekarar da ta ƙare Disamba 31, 2023, da fatan za a ziyarci bayanan Kamfanin a www.sedar.com.

Game da Innocan

Innocan kamfani ne na fasaha na harhada magunguna wanda ke aiki a ƙarƙashin manyan sassa biyu: Pharmaceuticals da Lafiyar Mabukaci. A cikin sashin Pharmaceuticals, Innocan yana mai da hankali kan haɓaka sabbin fasahohin dandamali na isar da magunguna dangane da ci-gaban kimiyyar cannabinoids, don magance yanayi daban-daban don haɓaka ingancin rayuwar marasa lafiya. Wannan ɓangaren ya ƙunshi fasahar isar da magunguna guda biyu: (i) LPT CBD-lokakken dandamali na liposome mai sauƙaƙe daidai gwargwado da tsawaitawa da sarrafawar sakin CBD cikin rafin jini. Binciken dandamali na bayarwa na LPT yana cikin lokacin gwaji na ainihi don alamu biyu: Gudanar da Ciwo da Farfaɗo. (ii) CLX CBD-loaded exosomes dandamali wanda zai iya riƙe yuwuwar samar da tasiri mai ƙarfi na haɓakawa da haɓakar ƙwayoyin cuta da ke niyya da tsarin juyayi na tsakiya. A cikin Sashin Lafiyar Mabukaci, Innocan yana haɓakawa kuma yana tallata babban fayil na sabbin samfuran kulawa da kai don haɓaka ingantaccen salon rayuwa. A ƙarƙashin wannan ɓangaren, Innocan ya kafa haɗin gwiwar haɗin gwiwa da sunan BI Sky Global Ltd. wanda ke mayar da hankali kan tallace-tallacen kan layi da aka yi niyya. https://innocanpharma.com

BABU KASAN KASASHEN CANADI DA SUKA SAUYA KO AYYUKAN HUKUNCINTA MAI SIFFOFI BA SU YI TATTAKI BA KO KARBATAR DA RUWAYOYI AKAN WANNAN SIFFOFIN KO INGANCIN WANNAN SAMUN.

Bayanin taka tsantsan game da bayanin sa ido

Wasu bayanan da aka bayyana a cikin wannan sakin labarai, gami da, ba tare da iyakancewa ba, bayanai game da bincike da haɓakawa, haɗin gwiwa, shigar da yuwuwar aikace-aikacen tare da FDA da sauran hukumomin gudanarwa, yuwuwar nasarar ci gaban matakan ƙa'ida na gaba, yuwuwar magance yanayi sauran tasirin warkewa da ya samo asali daga ayyukan bincike da/ko samfuran Kamfanin, amincewar ƙa'ida da lokacin shigar kasuwa, bayanai ne na gaba a cikin ma'anar dokokin tsaro. Ta yanayinsa, bayanin da ake sa ido yana fuskantar haɗari da rashin tabbas da yawa, wasu daga cikinsu sun wuce ikon Innocan. Bayanan da aka sa gaba da ke kunshe a cikin wannan sakin labarai ya dogara ne akan wasu mahimman tsammanin da zato da Innocan ya yi, ciki har da tsammanin da zato game da fa'idodin da ake tsammani na samfuran, gamsuwa da buƙatun ƙa'idodi a cikin yankuna daban-daban da kuma gamsuwar kammala samarwa da shirye-shiryen rarraba buƙatu. .

Bayanin neman gaba yana ƙarƙashin haɗari daban-daban da rashin tabbas waɗanda zasu iya haifar da sakamako na ainihi da ƙwarewa don bambanta ta zahiri daga sakamakon da ake tsammani ko tsammanin da aka bayyana a cikin wannan sakin labarai. Mabuɗin haɗari da rashin tabbas sun haɗa da amma ba'a iyakance ga: gabaɗaya na duniya da na gida (na ƙasa) tattalin arziki, kasuwa da yanayin kasuwanci; bukatun gwamnati da na ka'idoji da ayyuka na hukumomin gwamnati; da dangantaka da masu kaya, masana'antun, abokan ciniki, abokan kasuwanci da masu fafatawa. Hakanan akwai haɗarin da ke tattare da yanayin rarraba samfuran, gami da abubuwan shigo da kaya / fitarwa da gazawar samun duk wani tsari da ake buƙata da sauran yarda (ko yin hakan a kan kari) da samuwa a cikin kowane kasuwa na kayan aikin samfur da gamawa. samfurori. Tsarin lokacin da ake tsammani don shiga kasuwanni na iya canzawa saboda dalilai da yawa, gami da rashin iya tabbatar da buƙatun ƙa'idodi masu mahimmanci, ko buƙatar ƙarin lokaci don ƙarewa da / ko gamsar da shirye-shiryen masana'antu da rarrabawa. Sakamakon abin da ya gabata, masu karatu kada su dogara ga bayanan da ke ƙunshe a cikin wannan sakin labarai game da lokacin ƙaddamar da rarraba samfur. Ana iya samun cikakkiyar tattaunawa game da wasu haɗarin da ke tasiri Innocan a cikin rahotannin jama'a na Innocan da fayafai waɗanda ke samuwa a ƙarƙashin bayanin Innocan a www.sedar.com.

An gargadi masu karatu cewa bai kamata a sanya dogaro da bai dace ba akan bayanai na gaba saboda ainihin sakamakon na iya bambanta ta zahiri daga bayanan da ake nema. Innocan baya ɗaukar ɗaukakawa, gyara ko sake duba duk wani bayanin neman gaba sakamakon kowane sabon bayani, abubuwan da zasu faru nan gaba ko akasin haka, sai dai kamar yadda doka ta zartar.

• Ƙunshin Ƙarfafa SEO & Rarraba PR. Samun Girma a Yau.
• PlatoData.Network Tsaye Generative Ai. Karfafa Kanka. Shiga Nan.
• PlatoAiStream. Web3 Mai hankali. Ilmi Ya Faru. Shiga Nan.
• PlatoESG. Carbon, CleanTech, Kuzari, Muhalli, Solar, Gudanar da Sharar gida. Shiga Nan.
• PlatoHealth. Biotech da Clinical Trials Intelligence. Shiga Nan.
• Source: https://mgmagazine.com/press-releases/innocan-pharma-reports-full-year-2023-results/